Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Podcast: Improving Human Healthcare With Health-Related Quality Of Life (HRQoL) Assessments

Measuring the efficacy of a treatment beyond physical measures yields vital insights into the true value of a drug. Explore how HRQoL’s social, mental, and functional assessments contribute to a therapeutic’s success across the entire drug development lifecycle.

Don’t miss insights from Citeline and the experts at Advanced Clinical.

Listen now for expert perspectives on:

    • Defining and measuring HRQoL
    • Planning clinical trials with a focus on the importance of HRQoL
    • Incorporating HRQoL into today’s clinical trials: strategies for trial design
    • HRQoL reporting: requirements of global regulatory agencies and why they differ
    • Addressing both HRQoL and diversity requirements
    • Evolving with novel modalities: the future of HRQoL
    •  

Enjoyed this podcast? find part two here.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC150831

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel